The DESTINY‐Lung01 and DESTINY‐Lung02 studies have demonstrated the efficacy of DS8201 in HER2‐mutant NSCLC who have progressed after standard treatment or targeted HER2‐TKI therapy, with ORR of 54.9 and 53.8%, respectively, and a median duration of response of 8.2 months.348, 349. Here, ERBB2 is linked to non-small cell lung carcinoma.